Table 3.
Antithrombotic regimen at hospital discharge.
|
All N = 1,080 |
HBR N = 354 |
LBR N = 726 |
p-value | |
|---|---|---|---|---|
| DAPT, n (%) | 947 (87.7) | 229 (64.7) | 718 (98.9) | <0.01 |
| aspirin-clopidogrel, n (%) | 264 (24.4) | 116 (32.8) | 148 (20.4) | <0.01 |
| aspirin-prasugrel, n (%) | 587 (54.4) | 98 (27.7) | 489 (67.4) | <0.01 |
| aspirin-ticagrelor, n (%) | 96 (8.9) | 15 (4.2) | 81 (11.2) | <0.01 |
| TAT, n (%) | 123 (11.4) | 122 (34.5) | 1 (0.1) | <0.01 |
| DAPT-VKA, n (%) | 69 (6.4) | 68 (19.2) | 1 (0.1) | <0.01 |
| DAPT-DOAC, n (%) | 54 (5.0) | 54 (15.2) | 0 (0) | <0.01 |
| SAPT, n (%) | 6 (0.6) | 0 (0) | 6 (0.8) | 0.2 |
| OAC + SAPT, n (%) | 3 (0.3) | 3 (0.8) | 0 (0) | 0.04 |
| Only OAC, n (%) | 1 (0.1) | 0 (0) | 1 (0.1) | 1 |
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; HBR, high bleeding risk; LBR, low bleeding risk; TAT, triple antithrombotic therapy; VKA, vitamin K antagonist; SAPT, single antiplatelet therapy.